左旋多巴反应试验的发展历史及外科应用

doi:10.19854/j.cnki.1008-2425.2023.02.0013

摘要/Abstract

摘要： 左旋多巴反应试验是一项临床常用的简便有效的评价帕金森病患者多巴反应性的方法,对于帕金森病的诊断和指导药物治疗具有重要意义,也是外科脑深部电刺激手术(DBS)的患者筛选指标及术后疗效的预测因素之一。目前普遍认为左旋多巴反应试验的改善率大于30%适合DBS手术,然而关于改善率临界值尚存在争议。左旋多巴反应试验与手术患者筛选及术后疗效预测之间的关系也没有定论。了解左旋多巴反应试验的发展历史可以更科学地指导外科手术患者的筛选及个体化治疗。

关键词: 帕金森病, 左旋多巴反应试验, 脑深部电刺激手术, 手术患者筛选

中图分类号:

R742.5

贾小菲, 李继平, 张宇清. 左旋多巴反应试验的发展历史及外科应用[J]. 立体定向和功能性神经外科杂志, 2023, 36(2): 122-128.

参考文献

[1] Birkmayer W,Hornykiewicz O.[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia] [J].Wien Klin Wochenschr,1961,73:787~788.
[2] Yahr M D,Duvoisin R C,Schear M J,et al.Treatment of parkinsonism with levodopa[J].Arch Neurol,1969,21(4):343~354.
[3] Muenter M D,Tyce G M.L-dopa therapy of Parkinson's disease:plasma L-dopa concentration,therapeutic response,and side effects[J].Mayo Clin Proc,1971,46(4):231~239.
[4] Rabel C,Le Goff F,Lefaucheur R,et al.Subjective Perceived Motor Improvement after Acute Levodopa Challenge in Parkinson's Disease[J].J Parkinsons Dis,2016,6(4):779~785.
[5] Terroba Chambi C,Rossi M,Bril A,et al.Diagnostic Value of Combined Acute Levodopa Challenge and Olfactory Testing to Predict Parkinson's Disease[J].Mov Disord Clin Pract,2017,4(6):824~828.
[6] Postuma RB,Berg D,Stern M,et al.MDS clinical diagnostic criteria for Parkinson's disease[J].Mov Disord,2015,30(12):1591~1601.
[7] Schade S,Sixel-Doring F,Ebentheuer J,et al.Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease:Data from the DeNoPa Cohort[J].Mov Disord Clin Pract,2017,4(5):755~762.
[8] Lechien JR,Delsaut B,Abderrakib A,et al.Orofacial Strength and Voice Quality as Outcome of Levodopa Challenge Test in Parkinson Disease[J].Laryngoscope,2020,130(12):E896~e903.
[9] Rossi M,Perez-Lloret S,Merello M.How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?[J].Parkinsonism Relat Disord,2021,92:53~58.
[10] Quattrone A,Zappia M,Aguglia U,et al.The subacute levodopa test for evaluating long-duration response in Parkinson's disease[J].Ann Neurol,1995,38(3):389~395.
[11] Albanese A,Bonuccelli U,Brefel C,et al.Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease[J].Mov Disord,2001,16(2):197~201.
[12] Acharya M,Banerjee S,Chatterjee A,et al.Predicting Long-Term Outcome of Patients of Early Parkinsonism with Acute Levodopa Challenge Test[J].Neurol India,2021,69(2):430~434.
[13] Defer GL,Widner H,Marié RM,et al.Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)[J].Mov Disord,1999,14(4):572~584.
[14] Lang AE,Widner H.Deep brain stimulation for Parkinson's disease:patient selection and evaluation[J].Mov Disord,2002,17 Suppl 3:S94~101.
[15] Hariz M,Blomstedt P.Deep brain stimulation for Parkinson's disease[J].J Intern Med,2022,292(5):764~778.
[16] Nutt JG,Carter JH,Van Houten L,et al.Short-and long-duration responses to levodopa during the first year of levodopa therapy[J].Ann Neurol,1997,42(3):349~355.
[17] Esteguy M,Bonnet AM,Kefalos J,et al.[The L-dopa test in Parkinson's disease[J].Rev Neurol (Paris),1985,141(5):413~415.
[18] Barker R,Duncan J,Lees A.Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes[J].Lancet,1989,1(8639):675.
[19] Hughes AJ,Lees AJ,Stern GM.Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes[J].Lancet,1990,336(8706):32~34.
[20] Zappia M,Montesanti R,Colao R,et al.Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease[J].Mov Disord,1997,12(1):103~106.
[21] Merello M,Nouzeilles MI,Arce GP,et al.Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis[J].Mov Disord,2002,17(4):795~798.
[22] Saranza G,Lang AE.Levodopa challenge test:indications,protocol,and guide[J].J Neurol,2021,268(9):3135~3143.
[23] Clarke CE,Davies P.Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease[J].J Neurol Neurosurg Psychiatry,2000,69(5):590~594.
[24] Feng T,Li W,Lu L,et al.Acute stepwise challenge test with levodopa in treated patients with parkinsonism[J].Parkinsonism Relat Disord,2009,15(5):354~358.
[25] 中国帕金森病脑深部电刺激疗法专家组.中国帕金森病脑深部电刺激疗法专家共识[J].中华神经外科杂志,2012,(8):855~857.
[26] Hughes AJ,Lees AJ,Stern GM.Challenge tests to predict the dopaminergic response in untreated Parkinson's disease[J].Neurology,1991,41(11):1723~1725.
[27] Hughes AJ,Daniel SE,Kilford L,et al.Accuracy of clinical diagnosis of idiopathic Parkinson's disease:a clinico-pathological study of 100 cases[J].J Neurol Neurosurg Psychiatry,1992,55(3):181~184.
[28] Steiger MJ,Quinn NP.Levodopa challenge test in Parkinson's disease[J].Lancet,1992,339(8795):751~752.
[29] Müller T,Benz S.Quantification of the dopaminergic response in Parkinson's disease[J].Parkinsonism Relat Disord,2002,8(3):181~186.
[30] Moro E,Esselink RJ,Benabid AL,et al.Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation[J].Brain,2002,125(Pt 11):2408~2417.
[31] Moro E,Lang AE.Criteria for deep-brain stimulation in Parkinson's disease:review and analysis[J].Expert Rev Neurother,2006,6(11):1695~1705.
[32] Morishita T,Rahman M,Foote KD,et al.DBS candidates that fall short on a levodopa challenge test:alternative and important indications[J].Neurologist,2011,17(5):263~268.
[33] Sethi K.Levodopa unresponsive symptoms in Parkinson disease[J].Mov Disord,2008,23 Suppl 3:S521~533.
[34] Hoehn MM,Yahr MD.Parkinsonism:onset,progression and mortality[J].Neurology,1967,17(5):427~742.
[35] The Unified Parkinson's Disease Rating Scale (UPDRS):status and recommendations[J].Mov Disord,2003,18(7):738~750.
[36] Goetz CG,Fahn S,Martinez-Martin P,et al.Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS):Process,format,and clinimetric testing plan[J].Mov Disord,2007,22(1):41~47.
[37] Goetz CG,Stebbins GT,Tilley BC.Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores[J].Mov Disord,2012,27(10):1239~1242.
[38] Zappia M,Colao R,Montesanti R,et al.Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease[J].Ann Neurol,1997,42(2):245~248.
[39] Toru M,Matsuda O,Makiguchi K,et al.Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs[J].J Nerv Ment Dis,1981,169(5):324~327.
[40] Harada T,Mitsuoka K,Kumagai R,et al.Clinical features of malignant syndrome in Parkinson's disease and related neurological disorders[J].Parkinsonism Relat Disord,2003,9 Suppl 1:S15~23.
[41] 张羽钦,王兰,张波.左旋多巴骤然停用致撤药综合征[J].药物不良反应杂志,2016,(1):70~71.
[42] Lozano AM,Lang AE.Pallidotomy for Parkinson's disease[J].Adv Neurol,2001,86:413~420.
[43] 李明,李秀池,肖召安.帕金森病治疗的药物选择综述[J].中国药业,2016,25(10):94~96.
[44] 中华医学会神经外科学分会功能神经外科学组,中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍学组,et al.中国帕金森病脑深部电刺激疗法专家共识(第二版)[J].中华神经外科杂志,2020,(4):325~337.
[45] Contin M,Martinelli P.Pharmacokinetics of levodopa[J].J Neurol,2010,257(Suppl 2):S253~361.
[46] LeWitt PA.Levodopa therapy for Parkinson's disease:Pharmacokinetics and pharmacodynamics[J].Mov Disord,2015,30(1):64~72.
[47] Fabbri M,Coelho M,Abreu D,et al.Do patients with late-stage Parkinson's disease still respond to levodopa?[J].Parkinsonism Relat Disord,2016,26:10~16.
[48] Aygun D,Kocabicak E,Yildiz MO,et al.Effect of Age and Disease Duration on the Levodopa Response in Patients with Advanced Parkinson's Disease for Deep Brain Stimulation of the Subthalamic Nucleus[J].Front Neurol,2016,7:97.
[49] Vasta R,Nicoletti A,Mostile G,et al.Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms[J].PLoS One,2017,12(2):e0172145.
[50] Agid Y,Pollak P,Bonnet AM,et al.Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease[J].Lancet,1979,1(8116):570~572.
[51] Rogers G,Davies D,Pink J,et al.Parkinson's disease:summary of updated NICE guidance[J].Bmj,2017,358:j1951.
[52] Rossi P,Colosimo C,Moro E,et al.Acute challenge with apomorphine and levodopa in Parkinsonism[J].Eur Neurol,2000,43(2):95~101.
[53] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,(4):268~271.
[54] Gasser T,Schwarz J,Arnold G,et al.Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease[J].Arch Neurol,1992,49(11):1131~1134.
[55] Kulshreshtha D,Pieterman M,Gilmore G,et al.Optimizing the selection of Parkinson's disease patients for neuromodulation using the levodopa challenge test[J].J Neurol,2022,269(2):846~852.
[56] Bronstein JM,Tagliati M,Alterman RL,et al.Deep brain stimulation for Parkinson disease:an expert consensus and review of key issues[J].Arch Neurol,2011,68(2):165.
[57] Fukaya C,Watanabe M,Kobayashi K,et al.Predictive Factors for Long-term Outcome of Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease[J].Neurol Med Chir (Tokyo),2017,57(4):166~171.
[58] Bernardo WM,Rubira C,Silvinato A.Deep brain stimulation in parkinson disease[J].Rev Assoc Med Bras (1992),2019,65(4):541-546.
[59] Fernandez HH,Standaert DG,Hauser RA,et al.Levodopa-carbidopa intestinal gel in advanced Parkinson's disease:final 12-month,open-label results[J].Mov Disord,2015,30(4):500~509.
[60] Antonini A,Odin P,Pahwa R,et al.The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease:A Systematic Review[J].Adv Ther,2021,38(6):2854~2890.
[61] Chaudhuri KR,Antonini A,Pahwa R,et al.Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep:Results from a Meta-Analysis with 24-Month Follow-Up[J].J Parkinsons Dis,2022,12(7):2071~2083.
[62] Lopiano L,Rizzone M,Bergamasco B,et al.Deep brain stimulation of the subthalamic nucleus in PD:an analysis of the exclusion causes[J].J Neurol Sci,2002,195(2):167~170.
[63] Piboolnurak P,Lang AE,Lozano AM,et al.Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease[J].Mov Disord,2007,22(7):990~997.
[64] Schuepbach WMM TL,Schnitzler A,et al.Quality of life predicts outcome of deep brain stimulation in early Parkinson disease[J].Neurology,2019,92(24):1166.
[65] 杨春晖,苑青,吴曦,等.STN-DBS治疗左旋多巴冲击试验改善率较低的原发性帕金森病患者的短期疗效[J].中华神经外科杂志,2019,(12):1205~1209.
[66] Hashimoto T,Elder CM,Okun MS,et al.Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons[J].J Neurosci,2003,23(5):1916~1923.
[67] Artusi CA,Lopiano L,Morgante F.Deep Brain Stimulation Selection Criteria for Parkinson's Disease:Time to Go beyond CAPSIT-PD[J].J Clin Med,2020,9(12).
[68] Lo Buono V,Lucà Trombetta M,Palmeri R,et al.Subthalamic nucleus deep brain stimulation and impulsivity in Parkinson's disease:a descriptive review[J].Acta Neurol Belg,2021,121(4):837~847.
[69] Reich MM,Hsu J,Ferguson M,et al.A brain network for deep brain stimulation induced cognitive decline in Parkinson's disease[J].Brain,2022,145(4):1410~1421.
[70] Bove F,Genovese D,Moro E.Developments in the mechanistic understanding and clinical application of deep brain stimulation for Parkinson's disease[J].Expert Rev Neurother,2022,22(9):789~803.
[71] Wang MB,Boring MJ,Ward MJ,et al.Deep brain stimulation for parkinson's disease induces spontaneous cortical hypersynchrony in extended motor and cognitive networks[J].Cereb Cortex,2022,32(20):4480~4491.
[72] Kordower J H,Olanow C W,Dodiya H B,et al.Disease duration and the integrity of the nigrostriatal system in Parkinson's disease[J].Brain,2013,136(Pt 8):2419~2431.
[73] Kahn L,Mathkour M,Lee S X,et al.Long-term outcomes of deep brain stimulation in severe Parkinson's disease utilizing UPDRS III and modified Hoehn and Yahr as a severity scale[J].Clin Neurol Neurosurg,2019,179:67~73.
[74] Golfrè Andreasi N,Rispoli V,Contaldi E,et al.Deep brain stimulation and refractory freezing of gait in Parkinson's disease:Improvement with high-frequency current steering co-stimulation of subthalamic nucleus and substantia Nigra[J].Brain Stimul,2020,13(2):280~283.
[75] Roediger J,Artusi CA,Romagnolo A,et al.Effect of subthalamic deep brain stimulation on posture in Parkinson's disease:A blind computerized analysis[J].Parkinsonism Relat Disord,2019,62:122~127.
[76] Fabbri M,Coelho M,Guedes L C,et al.Response of non-motor symptoms to levodopa in late-stage Parkinson's disease:Results of a levodopa challenge test[J].Parkinsonism Relat Disord,2017,39:37~43.
[77] Mahlknecht P,Foltynie T,Limousin P,et al.How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?[J].Mov Disord,2022,37(8):1581~1592.
[78] Krause P,Reimer J,Kaplan J,et al.Deep brain stimulation in Early Onset Parkinson's disease[J].Front Neurol,2022,13:1041449.